BioCardia, Inc. (BCDA)

NASDAQ: BCDA · Delayed Price · USD
1.57
-0.02 (-1.26%)
At close: Jan 26, 2022 4:00 PM
1.55
-0.02 (-1.27%)
After-hours:Jan 26, 2022 6:38 PM EST

Company Description

BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases.

Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and ALLOGENEIC cell therapy for cardiac and pulmonary disease.

The company is also developing ALLOGENEIC Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure.

In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths.

The company is based in San Carlos, California.

BioCardia, Inc.
BioCardia Logo
CountryUnited States
IndustryBiotechnology
SectorHealth Care
Employees24
CEOPeter Altman

Contact Details

Address:
125 Shoreway Rd Ste B
San Carlos, California 94070-2718
United States
Phone650 226 0120
Websitebiocardia.com

Stock Details

Ticker SymbolBCDA
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0000925741

Key Executives

NamePosition
Dr. Peter A. AltmanChief Executive Officer, President and Director
David McClungChief Financial Officer
Dr. Ian McNiece Ph.D.Chief Scientific Officer
Edward M. GillisSenior Vice President of Devices
Dr. Sujith ShettyChief Medical Officer and Vice President of Clinical and Regulatory

Latest SEC Filings

DateTypeTitle
Dec 15, 20218-KCurrent report
Nov 18, 20214Statement of changes in beneficial ownership of securities
Nov 10, 20218-KCurrent report
Nov 10, 202110-QQuarterly report [Sections 13 or 15(d)]
Oct 21, 20218-KCurrent report
Oct 12, 20218-KCurrent report
Oct 7, 20218-KCurrent report
Sep 22, 2021SC 13DGeneral statement of acquisition of beneficial ownership
Sep 10, 20218-KCurrent report
Aug 18, 20214Statement of changes in beneficial ownership of securities
View All SEC Filings